Sheldon Cho v. H.I.G. Capital, LLC

CourtCourt of Appeals for the Eleventh Circuit
DecidedApril 1, 2022
Docket20-14109
StatusPublished

This text of Sheldon Cho v. H.I.G. Capital, LLC (Sheldon Cho v. H.I.G. Capital, LLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sheldon Cho v. H.I.G. Capital, LLC, (11th Cir. 2022).

Opinion

USCA11 Case: 20-14109 Date Filed: 04/01/2022 Page: 1 of 19

[PUBLISH] In the United States Court of Appeals For the Eleventh Circuit

____________________

No. 20-14109 ____________________

SHELDON CHO, MD, Relators and on behalf of the States of Florida, Colorado, Georgia, North Carolina and Texas, DAWN BAKER, Relators and on behalf of the States of Florida, Colorado, Georgia, North Carolina and Texas,

Plaintiffs-Appellants- Cross Appellees, versus SURGERY PARTNERS, INC., et al., USCA11 Case: 20-14109 Date Filed: 04/01/2022 Page: 2 of 19

2 Opinion of the Court 20-14109

Defendants,

H.I.G. CAPITAL, LLC, H.I.G. SURGERY CENTERS, LLC,

Defendants-Appellees- Cross Appellants.

Appeals from the United States District Court for the Middle District of Florida D.C. Docket No. 8:17-cv-00983-VMC-AEP ____________________

Before WILSON, LAGOA, Circuit Judges, and MARTINEZ*, District Judge. WILSON, Circuit Judge: The False Claims Act (FCA) allows private parties, known as qui tam relators, to bring suit on behalf of the United States against persons who submitted false claims to the government. In this case, Dawn Baker and Dr. Sheldon Cho (the Relators) allege that H.I.G. Capital, LLC and H.I.G. Surgery Centers, LLC (collectively,

*Honorable Jose E. Martinez, United States District Judge for the Southern District of Florida, sitting by designation. USCA11 Case: 20-14109 Date Filed: 04/01/2022 Page: 3 of 19

20-14109 Opinion of the Court 3

H.I.G. or the H.I.G. entities) spearheaded a fraudulent enterprise to submit false claims for reimbursement to Medicare and other government payors. The district court dismissed the claim without prejudice under the FCA’s first-to-file bar, which prohibits relators from bringing a qui tam action while a related action is pending. On appeal, the Relators argue that the district court’s first-to-file analysis was flawed because (1) it should have focused on the mo- ment at which they filed their amended complaint rather than their original complaint, and (2) the earlier-filed action the district court relied on is unrelated to this suit. On cross-appeal, H.I.G. argues that we should convert the district court’s dismissal without preju- dice to a dismissal with prejudice for failure to state a claim and for failure to meet the heightened pleading standard required for alle- gations of fraud—grounds the district court did not address below. After careful review and with the benefit of oral argument, we hold, first, that the FCA’s plain language makes the original complaint—not the amended complaint—the proper point of ref- erence for the first-to-file analysis. Second, we hold that this action is related to an earlier-filed action that alleged the same material elements of fraud. Therefore, we affirm the district court’s dismis- sal of the complaint without prejudice pursuant to the first-to-file bar. Finally, we deny H.I.G.’s cross-appeal. Even assuming we could enlarge H.I.G.’s relief based on grounds the district court did not reach, we decline to do so. USCA11 Case: 20-14109 Date Filed: 04/01/2022 Page: 4 of 19

4 Opinion of the Court 20-14109

I. We begin with an overview of the facts and procedural back- ground of this case. Because this is an appeal from a motion to dismiss, we take as true the facts pleaded in the complaint and con- strue them in the light most favorable to the Relators. Belanger v. Salvation Army, 556 F.3d 1153, 1155 (11th Cir. 2009). In 2009, H.I.G., an international private equity firm, pur- chased Surgery Partners, Inc., along with its subsidiaries and affili- ates (collectively, Surgery Partners). Surgery Partners owned and operated a network of surgery and pain-management centers. At the time of the acquisition, an H.I.G. affiliate entered into a man- agement contract with Surgery Partners, giving H.I.G. control over Surgery Partners’ operation. Shortly thereafter, H.I.G. placed three of its representatives on Surgery Partners’ Board of Directors. In 2011, H.I.G. and Surgery Partners formed a diagnostic testing business called Logan Laboratories, LLC (Logan Labs), which spe- cialized in urine drug testing (UDT). There are two types of UDT: qualitative, which can detect the presence of drugs in a patient’s system, and quantitative, which can detect how much of a drug is in a patient’s system. While quan- titative UDT has the advantage of providing more information, it is often not medically necessary. And because it must be per- formed in a laboratory, by laboratory professionals, it is more ex- pensive than qualitative UDT. USCA11 Case: 20-14109 Date Filed: 04/01/2022 Page: 5 of 19

20-14109 Opinion of the Court 5

The Relators allege that Surgery Partners—under H.I.G.’s guidance—consistently and routinely pressured its medical provid- ers to refer patients to Logan Labs for quantitative UDT, regardless of whether qualitative UDT, the cheaper option, would have been sufficient. Making matters worse, the Relators say, Logan Labs would run excessive UDT panels, thus further increasing costs. Based on these UDT panels, Logan Labs then submitted claims for reimbursement to government healthcare programs, generating millions of dollars in payments. The Relators allege that H.I.G. caused this fraudulent overbilling, evidenced by the fact that it con- trolled Surgery Partners and Logan Labs during the relevant time period. Several H.I.G. executives who sat on Surgery Partners’ Board of Directors allegedly furthered the fraud by manipulating Surgery Partners’ electronic medical records (EMR) software to justify unnecessary UDT. In April 2017, the Relators—a pain management specialist and a physician recruiter—filed a complaint under the FCA and several state fraud statutes alleging that dozens of defendants had engaged in a fraudulent scheme. The Relators amended their com- plaint as of right in January 2019. A year later, the United States intervened as to some defendants named in the action, but declined to intervene as to H.I.G. Importantly, however, a separate group of relators had also filed an FCA action (hereinafter, the Ashton Action) under seal against Surgery Partners and Logan Labs in connection with the same fraudulent scheme, though they did not name the H.I.G. USCA11 Case: 20-14109 Date Filed: 04/01/2022 Page: 6 of 19

6 Opinion of the Court 20-14109

entities as defendants. See United States ex rel. Ashton v. Logan Laboratories, LLC, et al., Case No. 16-4583 (E.D. Pa. 2016). The Ashton Action was filed in August 2016—eight months before the Relators filed their initial complaint. The United States eventually intervened in the Ashton Action and reached a $41 million settle- ment agreement with four defendants, the Relators in this case, and the Ashton relators. The settlement agreement, announced in April 2020, contained a general release of FCA liability for Logan Labs’ “current and former direct and indirect[ ] parent corporations . . . [and] corporate owners” based on the conduct described in the agreement. And specifically as to H.I.G., the agreement included a release of “liability against the H.I.G. Entities . . . for their own independent conduct outside their status as investors in or owners of” Logan Labs. The Ashton Action was then unsealed, and the settlement agreement became public. Subsequently, the Relators in this case filed a second amended complaint narrowing their allegations to focus on H.I.G.’s conduct. The second amended complaint brought causes of action against the H.I.G. entities for violation of the FCA, 31 U.S.C. § 3729(a)(1)(A) and (B), and for conspiracy to violate the FCA, 31 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bryant v. Avado Brands, Inc.
187 F.3d 1271 (Eleventh Circuit, 1999)
In Re Hedrick
524 F.3d 1175 (Eleventh Circuit, 2008)
Makro Capital of America, Inc. v. UBS AG
543 F.3d 1254 (Eleventh Circuit, 2008)
Belanger Ex Rel. Estate of Belanger v. Salvation Army
556 F.3d 1153 (Eleventh Circuit, 2009)
Rockwell International Corp. v. United States
549 U.S. 457 (Supreme Court, 2007)
Grynberg v. Koch Gateway Pipeline Co.
390 F.3d 1276 (Tenth Circuit, 2004)
Marc Wiersum v. U.S. Bank, N.A.
785 F.3d 483 (Eleventh Circuit, 2015)
Walburn v. Lockheed Martin Corp.
431 F.3d 966 (Sixth Circuit, 2005)
United States Ex Rel. Shea v. Cellco Partnership
863 F.3d 923 (D.C. Circuit, 2017)
Harris v. Garner
216 F.3d 970 (Eleventh Circuit, 2000)
United States ex rel. Heath v. AT & T, Inc.
791 F.3d 112 (D.C. Circuit, 2015)
United States ex rel. Wood v. Allergan, Inc.
899 F.3d 163 (Second Circuit, 2018)
United States ex rel. Carson v. Manor Care, Inc.
851 F.3d 293 (Fourth Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Sheldon Cho v. H.I.G. Capital, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sheldon-cho-v-hig-capital-llc-ca11-2022.